

Supplemental Material

Table of contents

| | |
|---|---|
| Supplemental Table 1. Patient Characteristics and Mean Annualized Spending, by Type of Dementia. | 4 |
| Supplemental Figure 1. Mean Total Pharmaceutical Spending Trend among Patients with Dementia. | 6 |

Supplemental Table 1. Patient Characteristics and Mean Annualized Spending, by Type of Dementia.

| Variable | Alzheimer's Disease (N=130,451) | Other Dementia (N=162,033) | P- Value ^a |
|---|------------------------------------|-------------------------------|--------------------------|
| Age (years), % | | | <0.001 |
| <65 | 2.9 | 9.4 | |
| 65-79 | 24.9 | 31.6 | |
| >80 | 72.2 | 59.1 | |
| Male, % | 28.5 | 34.9 | <0.001 |
| Race, % | | | <0.001 |
| White | 78.7 | 78.9 | |
| Black | 10.3 | 10.9 | |
| Asian | 2.2 | 2.4 | |
| Hispanic | 7.9 | 6.5 | |
| Native American | 0.3 | 0.5 | |
| Other | 0.6 | 0.8 | |
| Medicaid eligibility, % | 40.9 | 36.4 | <0.001 |
| CMS priority chronic conditions, % | | | |
| Depression | 64.3 | 56.7 | <0.001 |
| Diabetes mellitus | 46.5 | 47.2 | <0.001 |
| Acute myocardial infarction | 8.2 | 8.7 | <0.001 |
| Congestive heart failure | 51.5 | 50.1 | <0.001 |
| Previous stroke or TIA | 37.5 | 35.1 | <0.001 |
| Chronic kidney disease | 40.8 | 41.0 | 0.338 |
| Asthma | 16.5 | 18.7 | <0.001 |
| COPD | 40.1 | 41.5 | <0.001 |
| CMS priority cancer ^b | 18.4 | 18.4 | 0.720 |
| No. of other CMS priority comorbidities, % ^c | | | <0.001 |
| 0-3 | 8.8 | 12.9 | |
| 4-6 | 39.5 | 40.2 | |
| ≥7 | 51.7 | 46.9 | |
| Death within the year, % | 19.3 | 14.2 | <0.001 |
| Mean annualized spending in 2012 (2012 \$) | | | |
| Antidementia drugs ^d | 669 | 174 | <0.001 |
| Antipsychotics ^e | 317 | 293 | <0.001 |
| Antidepressants ^f | 121 | 114 | <0.001 |
| Sedatives ^f | 12 | 15 | <0.001 |
| Anticonvulsants ^f | 74 | 97 | <0.001 |
| Other NS drugs ^f | 82 | 139 | <0.001 |
| Total drugs acting on the NS | 1276 | 832 | <0.001 |
| Total pharmacy spending | 3080 | 2952 | <0.001 |

Notes:

Abbreviations: TIA=Transient Ischemic Attack; COPD=Chronic Obstructive Pulmonary Disease; CMS=Centers for Medicare and Medicaid Services; NS=Nervous System.

^a P-values were obtained using chi-square tests.

^b CMS priority types of cancer include breast cancer, colorectal cancer, endometrial cancer and lung cancer.


^c The number of other CMS priority conditions was calculated as the sum of a history of atrial fibrillation, cataract, glaucoma, hip or pelvic fracture, ischemic heart disease, osteoporosis, rheumatoid arthritis or osteoarthritis, hypertension, anemia, hyperlipidemia, benign prostatic hyperplasia and acquired hypothyroidism.

^d Antidementia drugs include any formulations containing donepezil, rivastigmine, galantamine or memantine.

^e Antipsychotics include any formulations containing aripiprazole, risperidone, quetiapine, olanzapine, ziprasidone, paliperidone, lurasidone, asenapine, clozapine, iloperidone, chlorpromazine, fluphenazine, haloperidol, loxapine, mesoridazine, moloindone, perphenazine, pimozide, promazine, tacrine, thioridazine, thiothixene, trifluoperazine or triflupromazine.

^f To identify antidepressants, sedatives, anticonvulsants and other drugs acting on the nervous system, we used the First Data Bank Enhanced Therapeutic Classification System.

Supplemental Figure 1. Mean Total Pharmaceutical Spending Trend among Patients with Dementia.



Notes:

Patients with other dementia includes patients with Alzheimer's disease related disorders and senile dementia.